Melanoma

Melanoma is one of the most aggressive forms of skin cancer, arising from malignant transformation of melanocytes and characterized by its capacity for rapid progression and metastasis. Early detection remains the most critical determinant of survival, making vigilant screening and precise diagnosis essential components of dermatologic practice. As a central oncologic focus in every global Dermatology Conference, this session explores advances in early recognition, molecular profiling, and targeted therapeutic innovation. Closely associated with malignant skin cancer management, melanoma care now integrates dermoscopic expertise, histopathologic staging, immunotherapy breakthroughs, and long-term surveillance strategies.

This session approaches melanoma from both clinical and molecular perspectives. Clinically, subtle asymmetry, evolving pigmentation, irregular borders, and atypical vascular patterns serve as early warning signs. Participants will review dermoscopic criteria that refine suspicion, including atypical pigment networks, blue-white veils, regression structures, and polymorphous vessels. Accurate staging based on Breslow thickness, ulceration status, and lymph node involvement guides prognosis and management decisions.

Molecular research has transformed melanoma treatment in recent years. The identification of mutations such as BRAF and NRAS has enabled development of targeted inhibitors that interrupt tumor growth pathways. Immune checkpoint inhibitors, including PD-1 and CTLA-4 blockers, have significantly improved survival in advanced disease. The session explores how these therapies alter immune surveillance and tumor microenvironment dynamics.

Surgical excision remains the primary treatment for localized melanoma, with margin determination guided by tumor depth. Sentinel lymph node biopsy and imaging studies support staging accuracy. For metastatic disease, systemic therapy and multidisciplinary oncology collaboration are emphasized.

Preventive strategies including sun protection education, high-risk population screening, and genetic counseling are discussed as proactive measures to reduce disease burden. Survivorship care and long-term monitoring are equally important, as recurrence risk persists even after successful treatment.

By integrating early detection with cutting-edge therapeutic advances, this session equips clinicians with the knowledge necessary to improve melanoma outcomes through precision-based, evidence-driven care.